Investors are recommended to buy Novo Nordisk and DexCom stocks for long-term growth potential

Novo Nordisk’s shares have underperformed in the past year, making them an attractive investment opportunity. Despite setbacks, the company has strong prospects in weight management and other therapeutic areas. With a diverse pipeline and reasonable valuation, Novo Nordisk is poised for growth. DexCom, a leader in diabetes-focused medical devices, has also faced challenges but has room for expansion. The company’s continuous glucose monitoring systems offer long-term growth potential, especially as insurance coverage increases. Both Novo Nordisk and DexCom have long-term investment appeal, presenting opportunities for investors seeking market-beating returns.

Read more at Nasdaq: 2 Stocks to Buy on the Dip and Hold for 10 Years